Mylan's (MYL) EpiPen Settlement is Credit-Negative Development - Moody's
- Wall Street turns defensive on Trump's protectionist stance
- Aetna's (AET) Humana (HUM) Takeover Blocked by Judge as Anticompetative
- Trump signs order withdrawing U.S. from Trans-Pacific trade deal
- Qualcomm (QCOM) Thrashed as Apple (AAPL) Lawsuit Threatens Licensing Business Model
- McDonald's (MCD) Tops Q4 EPS by 3c
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Moody's Investors Service commented that Mylan's (Nasdaq: MYL) settlement with the US Department of Justice and other government agencies to resolve EpiPen's reimbursement classification with the Centers for Medicaid and Medicare Services is a credit negative development. There are no changes to Mylan N.V.'s Baa3 rating or the stable ratings outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. health agency tells Grassley there is no EpiPen deal yet
- UPDATE: Seaport Global Securities Upgrades Flowserve Corp. (FLS) to Buy
- UPDATE: BMO Capital Upgrades Williams Partners LP (WPZ) to Outperform
Create E-mail Alert Related CategoriesCredit Ratings
Related EntitiesMoody's Investors Service
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!